Carol B. Lesser, MSN, RNC, NP, is a Nurse Practitioner at Boston IVF, Boston, MA.
Maryellen Matthews, RNC, is a Nurse Coordinator at Reproductive Medicine Associates of New Jersey (RMANJ) and is based in its Basking Ridge, NJ office.
Ms Lesser discloses that she received compensation from Actavis, Inc. for her participation in the preparation of this newsletter.
Ms Matthews discloses that she received compensation from Actavis, Inc. for her participation in the preparation of this newsletter.
The early IVF “fathers” were true visionaries who predicted the therapeutic use of preimplantation genetic diagnosis (PGD) as early as the 1960s. They immediately realized the possibility and desirability of determining an embryo’s genetic normalcy prior to transfer.1
